EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients
On 29 June, at the 12th Congress of the European Academy of Neurology (EAN) 2026, as part of a late-breaking…
Central Nervous System
-
-
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
-
AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis…
-
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Historically, migraine prevention has been managed with a wide variety of non-migraine-specific drug classes, such as beta-adrenergic receptor blockers, calcium…
-
Significant opportunities exist in the global pain market for novel mechanisms and modalities
Pain is a multifaceted, highly heterogeneous disorder that is treated using analgesics. There is a lack of diversity within the…
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
-
Biogen’s Tysabri to be used on England’s NHS for highly active MS
The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly active…
-
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by…
-
Nxera seeks schizophrenia programme buyer after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
